Research programme: Ebola virus therapeutics - Immunotech
Latest Information Update: 24 Oct 2014
At a glance
- Originator Immunotech Laboratories
- Class Proteins
- Mechanism of Action Immunostimulants; Viral fusion protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Ebola virus infections